[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-380955-105":59,"doc-detail-380955-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","strategies-to-target-the-cancer-driver-myc-in-tumor-cells","Strategies to target the cancer driver MYC in tumor cells","","The review explains how the MYC oncoprotein acts as a master regulator of cellular transcription while also performing non-transcriptional roles in DNA replication and cell-cycle control. Because MYC drives proliferation and survival and is aberrantly activated in most human tumors, it remains a major cancer driver despite being difficult to inhibit directly. It surveys direct and indirect MYC-inhibiting agents and summarizes strategies, including viral vectors and nanoparticles, to deliver MYC-targeting drugs into MYC-dependent tumor cells, emphasizing formulation and intracellular concentration.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/strategies-to-target-the-cancer-driver-myc-in-tumor-cells/380955/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/strategies-to-target-the-cancer-driver-myc-in-tumor-cells/380955.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is MYC considered a difficult target for direct inhibition?","Question",{"text":112,"@type":113},"MYC performs key non-enzymatic biochemical functions and has a largely unstructured surface, which has hindered the development of specific inhibitor compounds.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What types of strategies does the review cover to inhibit MYC?",{"text":117,"@type":113},"It covers both direct and indirect MYC-inhibiting agents, including organic compounds, nucleic acids, and peptides that interfere with MYC activities.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the review address delivering MYC-inhibiting agents to tumor cells?",{"text":121,"@type":113},"It summarizes current options to deliver drugs into cancer cells with derailed MYC, focusing on viral vectors and appropriate nanoparticles to achieve high intracellular compound concentrations.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},380955,1790366119,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","TYPE Review  \nPUBLISHED 08 March 2023 DOI 10.3389/fonc.2023.1142111  \nOPEN ACCESS  \nEDITED BY Yong Li,  \nBaylor College of Medicine, United States  \nREVIEWED BY Mushui Dai,  \nOregon Health and Science University, United States  \nKanaga Sabapathy, National Cancer Centre Singapore, Singapore  \n*CORRESPONDENCE Markus Hartl  \n [markus.hartl@uibk.ac.at](markus.hartl@uibk.ac.at)  \nSPECIALTY SECTION  \nThis article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology  \nRECEIVED 11 January 2023  \nACCEPTED 10 February 2023  \nPUBLISHED 08 March 2023  \nCITATION  \nWeber LI and Hartl M (2023)  \nStrategies to target the cancer driver MYC in tumor cells.  \nFront. Oncol. 13:1142111 .  \ndoi: 10.3389/fonc.2023.1142111  \nCOPYRIGHT  \n© 2023 Weber and Hartl. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nStrategies to target the cancer driver MYC in tumor cells  \nLeonie I. Weber and Markus Hartl*  \nInstitute of Biochemistry and Center of Molecular Biosciences (CMBI), University of Innsbruck, Innsbruck, Austria  \nThe MYC oncoprotein functions as a master regulator of cellular transcription and executes non-transcriptional tasks relevant to DNA replication and cell cycle regulation, thereby interacting with multiple proteins. MYC is required for fundamental cellular processes triggering proliferation, growth, differentiation, or apoptosis and also represents a major cancer driver being aberrantly activated in most human tumors. Due to its non-enzymatic biochemical functions and largely unstructured surface, MYC has remained difficult for specific inhibitor compounds to directly address, and consequently, alternative approaches leading to indirect MYC inhibition have evolved. Nowadays, multiple organic compounds, nucleic acids, or peptides specifically interfering with MYC activities are in preclinical or early-stage clinical studies, but none of them have been approved so far for the pharmacological treatment of cancer patients. In addition, specific and efficient delivery technologies to deliver MYC-inhibiting agents into MYC-dependent tumor cells are just beginning to emerge. In this review, an overview of direct and indirect MYC-inhibiting agents and their modes of MYC inhibition is given. Furthermore, we summarize current possibilities to deliver appropriate drugs into cancer cells containing derailed MYC using viral vectors or appropriate nanoparticles. Finding the right formulation to target MYC-dependent cancers and to achieve a high intracellular concentration of compounds blocking or attenuating oncogenic MYC activities could be as important as the development of novel MYC-inhibiting principles.  \nKEYWORDS  \ntranscriptional regulation, protein-protein interaction, cell proliferation, tumorigenesis, cell penetrating peptides, nanoparticles  \n1 MYC: An oncogenic transcription factor with pleiotropic functions  \n1.1 The MYC oncogene and its protein product  \nMYC gene is one of the most frequently deregulated oncogenes in many cancer types and a hallmark in the majority of human cancers (1) . The v-myc oncogene was originally discovered as the transforming principle in avian leukemogenic retroviruses (2–5) . The gene regulator MYC (c-MYC) and its paralogs MYCN (N-Myc) and MYCL (L-Myc) are  \nFrontiers in Oncology 01 [frontiersin.org](frontiersin.org)  \nbHLH-LZ proteins encompassing a protein dimerization domain (helix-loop-helix, leucine zipper) and a DNA contact surface (basic region), which are both located in the carboxyl-terminus (Figure 1) . The amino-termini of MYC proteins mediate crucial cellular functio","cbCaiopjfLO2mSKu","https://ap.wps.com/l/cbCaiopjfLO2mSKu","pdf",1561810,22,"English","# MYC: An oncogenic transcription factor with pleiotropic functions\n## The MYC oncogene and its protein product","[{\"question\":\"Why is MYC considered a difficult target for direct inhibition?\",\"answer\":\"MYC performs key non-enzymatic biochemical functions and has a largely unstructured surface, which has hindered the development of specific inhibitor compounds.\"},{\"question\":\"What types of strategies does the review cover to inhibit MYC?\",\"answer\":\"It covers both direct and indirect MYC-inhibiting agents, including organic compounds, nucleic acids, and peptides that interfere with MYC activities.\"},{\"question\":\"How does the review address delivering MYC-inhibiting agents to tumor cells?\",\"answer\":\"It summarizes current options to deliver drugs into cancer cells with derailed MYC, focusing on viral vectors and appropriate nanoparticles to achieve high intracellular compound concentrations.\"}]","Strategies to target the cancer driver MYC in tumor cells | PDF",1790242938,55]